Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK development pipeline underrated suggests Deutsche Bank
GSK's development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma's top R&D executives. Work needs to be done to rebuild the innovation proposition in the eyes of many investors, but Deutsche Bank sees clear emergent strands of underappreciated potential.
GSK plc: Long-Term Cash Cow
On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 million, up 46.6% from the previous quarter. The company has a rich pipeline of investigational vaccines and drugs, many of which have the potential to become "gold standards" in the fight against various viruses and disorders.
GSK found not guilty in Zantac trial
British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois, US, over its heartburn medication Zantac. A jury determined that Zantac was not responsible for the plaintiff's colon cancer, with the judge rejecting a request for $640 million in damages.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
GSK's GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.
GSK Breathes New Life Into Asthma Treatment With Depemokimab
GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinical trials. Financially, GSK shows solid earnings growth but has a current ratio below 1, indicating possible liquidity issues.
GSK: Zantac settlement could reach $2bn, says investment bank
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.
GSK: Zantac settlement could reach $2bn, says investment bank
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.
GSK says late-stage trials of potential blockbuster asthma drug met their goals
GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.
GSK's asthma drug shows promise in reducing severe attacks
GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.
GSK faces whistleblower lawsuit over Zantac cancer risk
GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug.
